靶向PI3激酶/Akt/mTOR信号通路。
Targeting the PI3-kinase/Akt/mTOR signaling pathway.
作者信息
Hassan Burhan, Akcakanat Argun, Holder Ashley M, Meric-Bernstam Funda
机构信息
Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, 6767 Bertner Avenue, Unit 0107, Houston, TX 77030, USA.
出版信息
Surg Oncol Clin N Am. 2013 Oct;22(4):641-64. doi: 10.1016/j.soc.2013.06.008. Epub 2013 Aug 6.
Abstract
This article presents an overview of the PI3K/Akt/mTOR signaling pathway. As a central regulator of cell growth, protein translation, survival, and metabolism, activation of this signaling pathway contributes to the pathogenesis of many tumor types. Biochemical and genetic aberrations of this pathway observed in various cancer types are explored. Last, pathway inhibitors both in development and already approved by the Food and Drug Administration are discussed.
摘要
本文概述了PI3K/Akt/mTOR信号通路。作为细胞生长、蛋白质翻译、存活和代谢的核心调节因子，该信号通路的激活促成了多种肿瘤类型的发病机制。文中探讨了在各种癌症类型中观察到的该通路的生化和基因异常情况。最后，还讨论了正在研发以及已获美国食品药品监督管理局批准的该通路抑制剂。
相似文献
1
Targeting the PI3-kinase/Akt/mTOR signaling pathway.
Surg Oncol Clin N Am. 2013 Oct;22(4):641-64. doi: 10.1016/j.soc.2013.06.008. Epub 2013 Aug 6.
2
Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.
Pharmacol Ther. 2014 May;142(2):164-75. doi: 10.1016/j.pharmthera.2013.12.004. Epub 2013 Dec 9.
3
Targeting the PI3K/Akt/mTOR pathway for breast cancer therapy.
J Mammary Gland Biol Neoplasia. 2012 Dec;17(3-4):205-16. doi: 10.1007/s10911-012-9264-2. Epub 2012 Aug 4.
4
PI3K/Akt/mTOR signaling in medullary thyroid cancer: a promising molecular target for cancer therapy.
Endocrine. 2015 Mar;48(2):363-70. doi: 10.1007/s12020-014-0380-1. Epub 2014 Aug 13.
5
PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside.
Semin Cancer Biol. 2019 Dec;59:125-132. doi: 10.1016/j.semcancer.2019.07.009. Epub 2019 Jul 16.
6
Targeting the PI3K-AKT-mTOR signaling network in cancer.
Chin J Cancer. 2013 May;32(5):253-65. doi: 10.5732/cjc.013.10057.
7
Targeting PI3K/AKT/mTOR network for treatment of leukemia.
Cell Mol Life Sci. 2015 Jun;72(12):2337-47. doi: 10.1007/s00018-015-1867-5. Epub 2015 Feb 25.
8
Targeting the PI3K/AKT/mTOR pathway: biomarkers of success and tribulation.
Am Soc Clin Oncol Educ Book. 2013. doi: 10.1200/EdBook_AM.2013.33.e395.
9
The phosphoinositide-3-kinase-Akt-mTOR pathway as a therapeutic target in breast cancer.
J Natl Compr Canc Netw. 2013 Jun 1;11(6):670-8. doi: 10.6004/jnccn.2013.0086.
10
Targeting the PI3K/Akt/mTOR pathway in malignancy: rationale and clinical outlook.
BioDrugs. 2014 Aug;28(4):373-81. doi: 10.1007/s40259-014-0090-5.
引用本文的文献
1
Molecular interplay of ARID1A in gastrointestinal cancers.
Med Oncol. 2025 Aug 23;42(10):442. doi: 10.1007/s12032-025-03014-7.
2
Angiosarcoma: a systematic review of biomarkers in diagnosis, prognosis, and therapeutic strategies.
Front Oncol. 2025 Jul 1;15:1623327. doi: 10.3389/fonc.2025.1623327. eCollection 2025.
3
Bioinformatic and genomic analysis identifies C allele of APOE rs7412 as the most prominent variant limiting extreme human longevity.
Sci Rep. 2025 Jul 1;15(1):21688. doi: 10.1038/s41598-025-02848-5.
4
The Histomorphology to Molecular Transition: Exploring the Genomic Landscape of Poorly Differentiated Epithelial Endometrial Cancers.
Cells. 2025 Mar 5;14(5):382. doi: 10.3390/cells14050382.
5
Exploration of the mechanism of Lithospermum erythrorhizon oil in treating atopic dermatitis based on network pharmacology and experimental validation of the PI3K-Akt pathway regulation.
Heliyon. 2025 Jan 10;11(2):e41707. doi: 10.1016/j.heliyon.2025.e41707. eCollection 2025 Jan 30.
6
Plant protein-derived anti-breast cancer peptides: sources, therapeutic approaches, mechanisms, and nanoparticle design.
Front Pharmacol. 2025 Jan 17;15:1468977. doi: 10.3389/fphar.2024.1468977. eCollection 2024.
7
Soybean isoflavone promotes milk yield and milk fat yield through the ERα-mediated Akt/mTOR pathway in dairy goats.
J Anim Sci. 2024 Jan 3;102. doi: 10.1093/jas/skae352.
8
Megalin: A Sidekick or Nemesis of the Kidney?
J Am Soc Nephrol. 2025 Feb 1;36(2):293-300. doi: 10.1681/ASN.0000000572. Epub 2024 Nov 15.
9
Landscape of targeted therapies for lung squamous cell carcinoma.
Front Oncol. 2024 Oct 31;14:1467898. doi: 10.3389/fonc.2024.1467898. eCollection 2024.
10
Emerging roles of non-coding RNAs in modulating the PI3K/Akt pathway in cancer.
Noncoding RNA Res. 2024 Aug 9;10:1-15. doi: 10.1016/j.ncrna.2024.08.002. eCollection 2025 Feb.
本文引用的文献
1
Defining biomarkers to predict sensitivity to PI3K/Akt/mTOR pathway inhibitors in breast cancer.
Cancer Treat Rev. 2013 Jun;39(4):313-20. doi: 10.1016/j.ctrv.2012.11.002. Epub 2012 Dec 6.
2
Comprehensive molecular portraits of human breast tumours.
Nature. 2012 Oct 4;490(7418):61-70. doi: 10.1038/nature11412. Epub 2012 Sep 23.
3
Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.
Clin Cancer Res. 2012 Oct 15;18(20):5816-28. doi: 10.1158/1078-0432.CCR-12-1141. Epub 2012 Aug 29.
4
Sequence analysis of mutations and translocations across breast cancer subtypes.
Nature. 2012 Jun 20;486(7403):405-9. doi: 10.1038/nature11154.
5
The landscape of cancer genes and mutational processes in breast cancer.
Nature. 2012 May 16;486(7403):400-4. doi: 10.1038/nature11017.
6
mTOR signaling in growth control and disease.
Cell. 2012 Apr 13;149(2):274-93. doi: 10.1016/j.cell.2012.03.017.
7
PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors.
Clin Cancer Res. 2012 Mar 15;18(6):1777-89. doi: 10.1158/1078-0432.CCR-11-2123.
8
The translational landscape of mTOR signalling steers cancer initiation and metastasis.
Nature. 2012 Feb 22;485(7396):55-61. doi: 10.1038/nature10912.
9
Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background.
Mol Cancer Ther. 2012 Apr;11(4):873-87. doi: 10.1158/1535-7163.MCT-11-0824-T. Epub 2012 Jan 31.
10
The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia.
Leukemia. 2012 Jun;26(6):1195-202. doi: 10.1038/leu.2011.339. Epub 2011 Dec 6.
Zotero 插件